
Seattle-based Magnolia Medical Technologies manufactures devices to enhance diagnostic blood culture accuracy.
magnolia-medical.comCrawled Oct 15, 2026
Understand the differences between aerobic and anaerobic bacteria and their clinical significance in diagnosing bloodstream infections.
Home / News & Media / Everyday Hero: Hartley
Home / News & Media / Everyday Heroes: Angela
A report dated July 13, 2023, presents perspectives and findings on hospitalization concerns, antimicrobial stewardship, infection concerns, sepsis, and hospital-acquired infections.
Going Blue: Confronting the AMR Challenge presents insights and strategies related to antimicrobial resistance.
A report dated August 30, 2023, presents perspectives and findings about sepsis.
Christine joined Magnolia Medical Technologies as vice president of marketing in October 2021 and oversees marketing, product and portfolio prioritization, digital marketing, and demand generation.
Erik has 20 years of experience in the life sciences and medical device sectors. Since July 2024, he has been chief financial officer at Magnolia Medical Technologies, overseeing finance and revenue operations.
Jessica has over 25 years of cross-industry experience. She most recently supported learning and development at TwinStrand Biosciences and previously was vice president of human resources and information technology at an e-commerce luxury goods company.
Home / Leadership / Paul Goldenbaum, PhD
The page provides information about Steripath and reducing false-positive blood cultures.
Magnolia Medical Technologies, proud makers of the Steripath Micro Initial Specimen Diversion Device for blood culture testing integrity.
Magnolia Medical Technologies, Inc. says its privacy policy describes its practices for collecting and disseminating information through its website and services that link to or refer to the policy.